Latest revenue
$5.1M
as of 2025-12-31
Latest net income
$-57.6M
as of 2025-12-31
Net margin
-1120.7%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think AARD is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $80.7M
- Enterprise value
- $18.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.93×
- Dividend yield
- 0.0%
- 52-wk high
- $17.94
- 52-wk low
- $3.35
- Beta
- —
- Shares out
- 21.8M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients. We have focused our efforts on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Our initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the chemicals in food and participate in the gut-brain axis. Our research has shown that activating these…
AI summary unavailable — showing raw filing excerpt
Generated from AARD's filing dated 2026-03-23
Key risks
Item 1A. Risk Factors. An investment in our common stock involves a high degree of risk. In deciding whether to invest, you should carefully consider and read the following risk factors, as well as the financial and other information contained in this Annual Report, including in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, of this Annual Report and in our consolidated financial statements and related notes thereto included elsewhere in this Annual Report. Any of the following risks could have a material adverse effect on our business, financial condition, results of operations or prospects and cause the value of our common stock…
AI summary unavailable — showing raw filing excerpt
Generated from AARD's filing dated 2026-03-23
Profitability
Operating margin
-1220.6%
29.3%Net margin
-1120.7%
31.4%Return on equity
-54.0%
243.3%Return on assets
-49.1%
85.0%Leverage
Debt / equity
0.10×
104.1%Debt / assets
9.0%
94.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-21.6M | -131.9% | — |
Q4 2025 2025-12-31 | — | — | $-17.6M | -100.5% | — |
Q3 2025 2025-09-30 | — | — | $-16.3M | -290.1% | — |
Q2 2025 2025-06-30 | — | — | $-14.4M | -163.7% | — |
Q1 2025 2025-03-31 | — | — | $-9.3M | -327.5% | — |
Q4 2024 2024-12-31 | — | — | $-8.8M | — | — |
Q3 2024 2024-09-30 | — | — | $-4.2M | — | — |
Q2 2024 2024-06-30 | — | — | $-5.4M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AARD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$450.3K
Insider selling
$0
Net activity
+$450.3K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AARD
Institutional value
$21.7M
Total shares held
5.8M
Distinct holders
37
-29 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Decheng Capital LLC | 3.9M | $14.8M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 792.6K | $3.0M | +8.1K (+1.0%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 554.1K | $2.1M | — | New |
| 4 | UBS Group AG | 157.9K | $595.2K | +131.1K (+488.3%) | Added |
| 5 | VANGUARD FIDUCIARY TRUST CO | 83.2K | $313.7K | — | New |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 75.1K | $283.3K | — | New |
| 7 | CITIGROUP INC | 46.3K | $174.4K | +45.4K (+5063.5%) | Added |
| 8 | Bank of New York Mellon Corp | 29.3K | $110.5K | +6.9K (+30.8%) | Added |
| 9 | DEUTSCHE BANK AG\ | 17.9K | $67.5K | +11.5K (+180.3%) | Added |
| 10 | ALPS ADVISORS INC | 17.7K | $66.8K | -150 (-0.8%) | Trimmed |
| 11 | Nuveen, LLC | 15.3K | $57.7K | -25.7K (-62.7%) | Trimmed |
| 12 | RHUMBLINE ADVISERS | 6.7K | $25.2K | -875 (-11.6%) | Trimmed |
| 13 | JPMORGAN CHASE & CO | 6.6K | $24.1K | -266 (-3.9%) | Trimmed |
| 14 | Vanguard Global Advisers, LLC | 5.9K | $22.2K | — | New |
| 15 | WELLS FARGO & COMPANY/MN | 4.7K | $17.7K | -9.4K (-66.6%) | Trimmed |
| 16 | Steward Partners Investment Advisory, LLC | 4.2K | $15.6K | — | New |
| 17 | China Universal Asset Management Co., Ltd. | 3.9K | $14.6K | +316 (+8.9%) | Added |
| 18 | NEW YORK STATE COMMON RETIREMENT FUND | 3.8K | $14.4K | +0 (+0.0%) | No change |
| 19 | BNP PARIBAS FINANCIAL MARKETS | 3.2K | $12.2K | -12.6K (-79.6%) | Trimmed |
| 20 | Police & Firemen's Retirement System of New Jersey | 2.1K | $8.0K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AARD's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.